First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas.
Justicia-Lirio P, Tristán-Manzano M, Maldonado-Pérez N, Barbero-Jiménez C, Cortijo-Gutiérrez M, Pavlovic K, Molina-Estevez FJ, Muñoz P, Hinckley-Boned A, Rodriguez-Madoz JR, Prosper F, Griñán-Lison C, Navarro-Marchal SA, Panisello C, Muñoz-Ballester J, González-Sierra PA, Herrera C, Marchal JA, Martín F.
Justicia-Lirio P, et al. Among authors: pavlovic k.
Mol Ther Nucleic Acids. 2024 Aug 15;35(4):102308. doi: 10.1016/j.omtn.2024.102308. eCollection 2024 Dec 10.
Mol Ther Nucleic Acids. 2024.
PMID: 39640015
Free PMC article.